A practical reference on PPAR delta: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-04. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
=== Effect on developing countries === Apart from the impact on Arab States of the Persian Gulf, the resulting economic disruptions after the crisis affected many states. The Overseas Development Institute (ODI) undertook a study in 1991 to assess the effects on developing states and the international community's response. A briefing paper finalized on the day that the conflict ended draws on their findings which had two main conclusions: Many developing states were severely affected and while there has been a considerable response to the crisis, the distribution of assistance was highly selective. The ODI factored in elements of "cost" which included oil imports, remittance flows, re-settlement costs, loss of export earnings and tourism. For Egypt, the cost totaled $1 billion, 3% of GDP. Yemen had a cost of $830 million, 10% of GDP, while it cost Jordan $1.8 billion, 32% of GDP. International response to the crisis on developing states came with the channeling of aid through The Gulf Crisis Financial Co-ordination Group. They were 24 states, comprising most of the OECD countries plus some Gulf states: Saudi Arabia, United Arab Emirates, Qatar and Kuwait. The members of this group agreed to disperse $14 billion in development assistance. The World Bank responded by speeding up the disbursement of existing project and adjustment loans. The International Monetary Fund adopted two lending facilities – the Enhanced Structural Adjustment Facility (ESAF) and the Compensatory & Contingency Financing Facility (CCFF). The European Community offered $2 billion in assistance.
=== Bee–Ber === Lorena S. Beese(20th–21st century). Biochemist at Duke University, known for structural biochemistry of DNA replication and protein prenylation enzymes. Member Natl. Acad. Sci. USA. Helmut Beinert (1913–2007). German born-American biochemist at the University of Wisconsin–Madison, a pioneer of and advocate for the use of electron paramagnetic resonance in biological systems. Member Natl. Acad. Sci. USA. Marlene Belfort (b. 1945). American biochemist at the New York State Department of Health involved in the discovery of self-splicing introns in bacteriophage. Member Natl. Acad. Sci. USA. Boris Pavlovich Belousov (1893–1970). Chemist and biophysicist in the Ministry of Health of the USSR who discovered the Belousov–Zhabotinsky reaction. Awarded the Lenin Prize (1980). Myron L. Bender (1924–1988). American biochemist at Northwestern University, who pioneered mechanistic studies of enzymes, especially chymotrypsin and other proteases. Member Natl. Acad. Sci. USA. Stephen J. Benkovic (b. 1938). American bioorganic chemist at Pennsylvania State University. Member Natl. Acad. Sci. USA. Steven A. Benner (b. 1954). American chemist at the University of Florida known for establishing synthetic biology and paleogenetics, aas wll as contributing to understanding of the origin of life; Paul Berg FRS (foreign member) (1926–2023). American biochemist at Stanford, known for pioneering work involving gene splicing of recombinant DNA. He was awarded the Nobel Prize in Chemistry in 1980. Helen M. Berman (b. 1943).
=== Cow's grass === In Ireland, before the 19th century, a "cow's grass" was a measurement used by farmers to indicate the size of their fields. A cow's grass was equal to the amount of land that could produce enough grass to support a cow.
PFOA is also formed as an unintended byproduct in the production of fluorotelomers and is present in finished goods treated with fluorotelomers, including those intended for food contact. Fluorotelomers are applied to food contact papers because they are lipophobic: they prevent oil from soaking into the paper from fatty foods. Also, fluorotelomers can be metabolized into PFOA. In a U.S. Food and Drug Administration (USFDA) study, lipophobic fluorotelomer-based paper coatings (which can be applied to food contact paper in the concentration range of 0.4%) were found to contain 88,000–160,000 parts per billion PFOA before application, while the oil from microwave popcorn bags contained 6–290 parts per billion PFOA after heating. Toxicologists estimate that microwave popcorn could account for about 20% of the PFOA levels measured in an individual consuming 10 bags a year if 1% of the fluorotelomers are metabolized to PFOA. In 2008 as news stories began to raise concerns about PFOA in microwaved popcorn, Dan Turner, DuPont's global public relations chief, said, "I serve microwave popcorn to my three-year-old." Five years later, journalist Peter Laufer wrote to Turner to ask if his child was still eating microwave popcorn. "I am not going to comment on such a personal inquiry", Turner replied. Fluorotelomer coatings are used in fast food wrappers, candy wrappers, and pizza box liners. PAPS, a type of paper fluorotelomer coating, and PFOA precursor, is also used in food contact papers.
In November 2024, after state analysts released a report showing that the state would soon enter a revenue deficit worse than the Great Recession, Moore reiterated a "high bar" for raising taxes and proposed temporarily pausing certain programs that were being implemented under the Blueprint for Maryland's Future. He also proposed shifting state investments toward growing areas of the state's economy—life sciences, information technology, and national defense—and coordinating economic development strategies with local governments. In January 2025, Moore proposed a budget that included $2 billion in spending cuts toward government programs that he described as "not effective nor sustainable", later signing an executive order aimed at reducing inefficiencies in state government. The proposed budget also contained an estimated $819 million in tax reforms, which included new income tax brackets for wealthy individuals and households, and a consolidation of income tax brackets for lower earners; an elimination of the state's inheritance tax and standard deductions; and a cut to the state's corporate tax rate while also requiring combined reporting for companies with subsidiaries. In March 2025, Moore told reporters that he did not support including a sugary drink tax or a "broad business-to-business tax" on services in his budget, but administration officials later told reporters that Moore would consider a package that also included taxes on services direct to consumers as well as businesses.
Sources: en.wikipedia.org
=== Centers for Disease Control and Prevention (CDC) === The CDC focuses on the analysis, research, and technical assistance within the CLIA partnership. In particular, the CDC establishes technical standards and guidelines, conducting studies, monitoring practices, and developing resources. In addition, the CDC manages the Clinical Laboratory Improvement Advisory Committee (CLIAC). CLIAC is made up of experts in many specialties throughout clinical and anatomic pathology that provide guidance and advice on general issues within laboratory science. The CDC specifically acknowledges that point-of-care testing simply describes the location at which the testing is performed and not the complexity of the test itself. With technological innovation, more complex tests will be able to be performed at the bedside that may not be CLIA-waived like some other at-home point of care tests that the FDA has waived such as urine dipsticks.
Regarding this, San Francisco attorney Alex Coolman has commented, "It's remarkable that Chidester's parents, and only Chidester's parents, continue to be cited over and over again by the mainstream media in their coverage of the supposed 'controversy' over the risks of Salvia divinorum." Kathleen Chidester has continued campaigning for "Schedule I"-like legislation beyond their home state of Delaware. For example, three years after Brett's death, in written testimony in support of Senator Richard Colburn's proposed Senate Bill to the Maryland State Legislature, saying, "My hope and goal is to have salvia regulated across the US. It's my son's legacy and I will not end my fight until this happens."
Metenolone, also known as 1-methyl-4,5α-dihydro-δ1-testosterone (1-methyl-δ1-DHT) or as 1-methyl-5α-androst-1-en-17β-ol-3-one, is a synthetic androstane steroid and derivative of dihydrotestosterone (DHT). A closely related AAS is mesterolone (1α-methyl-DHT).
March 26 COVID-19 pandemic Maine reports its first case of the Lineage P.1 variant, which was originally detected in Brazil. Wisconsin confirms their first cases of the Lineage P.1 and 501.V2 variants of SARS-CoV-2. Arizona reports its first case of the 501.V2 variant, which was originally detected in South Africa. New Jersey amends its alcohol and cannabis laws to allow police to notify parents or guardians after a first-time offense by a minor, following strong opposition to the prohibition on first-time notifications implemented when New Jersey legalized cannabis the previous month. The U.S. Food and Drug Administration (FDA) approves Abecma to treat multiple myeloma. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. March 29 In Minnesota, opening statements begin at the trial of former police officer Derek Chauvin, who is accused of murdering 46-year-old black man George Floyd by kneeling on his neck. The Arkansas Senate passed, HB1570, a bill that prohibited normally functioning and physically healthy minors from puberty blockers, cross-sex hormones, and genital and non-genital invasive surgical alterations. A judge orders three men charged with plotting to kidnap Michigan Governor Gretchen Whitmer to stand trial, after a three-day preliminary hearing. Threat of terrorism charges are also dismissed against two of the defendants. Killing of Adam Toledo – A 13-year-old Latino boy, Adam Toledo, is shot and killed by an officer of the Chicago Police Department.
Sources: en.wikipedia.org
As President, Johnson steadfastly pursued the Gemini and Apollo programs, promoting them as Kennedy's legacy to the American public. One week after Kennedy's death, he issued Executive Order 11129 renaming the Cape Canaveral and Apollo launch facilities after Kennedy.
Cardiac output (CO) is a measurement of the amount of blood pumped by each ventricle (stroke volume) in one minute. This is calculated by multiplying the stroke volume (SV) by the beats per minute of the heart rate (HR). So that: CO = SV x HR. The cardiac output is normalized to body size through body surface area and is called the cardiac index. The average cardiac output, using an average stroke volume of about 70mL, is 5.25 L/min, with a normal range of 4.0–8.0 L/min. The stroke volume is normally measured using an echocardiogram and can be influenced by the size of the heart, physical and mental condition of the individual, sex, contractility, duration of contraction, preload and afterload. Preload refers to the filling pressure of the atria at the end of diastole, when the ventricles are at their fullest. A main factor is how long it takes the ventricles to fill: if the ventricles contract more frequently, then there is less time to fill and the preload will be less. Preload can also be affected by a person's blood volume. The force of each contraction of the heart muscle is proportional to the preload, described as the Frank-Starling mechanism. This states that the force of contraction is directly proportional to the initial length of muscle fiber, meaning a ventricle will contract more forcefully, the more it is stretched. Afterload, or how much pressure the heart must generate to eject blood at systole, is influenced by vascular resistance. It can be influenced by narrowing of the heart valves (stenosis) or contraction or relaxation of the peripheral blood vessels.
=== Legal categorization and legal issues in a near future === Currently, siRNAs are chemically synthesized and are therefore legally categorized in the EU and the US as simple medicinal products. But as bioengineered siRNA (BERAs) are in development, these would be classified as biological medicinal products, at least in the EU. The development of the BERAs technology raises the question of the categorization of drugs having the same mechanism of action but being produced chemically or biologically. This lack of consistency should be addressed.
== Treatment == There is no direct cure for Hypermobility Spectrum Disorder, but its symptoms can be treated. Physiotherapy, particularly exercise, is the main treatment for the condition, although there is only limited evidence for its effectiveness.
Anthropologists argue that a biomedical focus places emphasis on the biological processes of fixing the body thereby disregarding holistic ideals of health and aging. By relying on a wholly medical approach, Western biomedicine can become blindsided by bodily dysfunctions which can be understood as appropriate functions of age, and not as a medical problem. Anthropologists understand that a biosocial approach to ED considers a person's decision to undergo clinical treatment more likely a result of "society, political economy, history, and culture" than a matter of personal choice. In rejecting biomedical treatment for ED, males can challenge common forms of medicalized social control by deviating from what is considered the normal approach to dysfunction.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.